The demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
Phase III success for Roche breast cancer drug
Latest NewsRoche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.
Pioneers in the synbio revolution
BackgroundIs synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players in the field believe the answer lies in miniaturising standard chemical processes and running them in parallel systems. But the new kids on the block are betting on a completely new process that involves enzymes.
Targovax reports promising disease-free survival (DFS) data
Latest NewsCutting time to market for high quality therapeutics
BackgroundThe demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
EU set to speed up switch to bioeconomy by new action plan
Latest NewsSix years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
Latest NewsT cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Affimed halts trial after patient death and SAEs
Latest NewsGenentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.
Aglaris Appoints New CEO
AppointmentsAglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
IMI fosters antibiotics research amidst Big Pharma pullbacks
BackgroundThe Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme.
Sitryx Therapeutics bags $30m in Series A Financing
Latest NewsOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.